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Available online 7 November 2017Vibrios are common inhabitants of marine and estuarine environments. Some of them can be pathogenic to
humans and/or marine animals using a broad repertory of virulence factors. Lately, several reports have
indicated that the incidence of Vibrio infections in humans is rising and also in animals constitute a continuing
threat for aquaculture. Moreover, the continuous use of antibiotics has been accompanied by an emergence of
antibiotic resistance in Vibrio species, implying a necessity for efﬁcient treatments. One promising alternative
that emerges is the use of lytic bacteriophages; however, there are some drawbacks that should be overcome
to make phage therapy a widely accepted method. In this work, we discuss about the major pathogenic Vibrio
species and the progress, beneﬁts and disadvantages that have been detected during the experimental use of
bacteriophages to their control.
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Vibrios are Gram-negative bacteria that can be found in marine and
estuarine environments. This genus comprises several pathogenicidad Católica de Valparaíso.
araíso. Production and hosting by Elsspecies for humans and animals. The most clinically important
pathogens for humans are Vibrio cholerae [1], V. parahaemolyticus [2]
and V. vulniﬁcus [3]; however, other species such as V. ﬂuvialis and
V. mimicus have been also associated with clinical cases [4,5]. V. cholerae
is responsible for several large outbreaks of cholera, including Haiti
in 2011 [6], while V. parahaemolyticus, although is able to cause
severe mortality in aquatic animal species [7,8], in this case will be
considered as human pathogen since is a major cause of severe diarrheaevier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
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is also the most common non-cholera Vibrio species reported to cause
infection. However, the most lethal food-transmitted pathogen in USA
and possibly in the world is V. vulniﬁcus [3].
On the other hand, the major pathogenic vibrios for animals are
V. anguillarum, V. ordalii and Vibrio harveyi. The ﬁrst two are the ones
responsible of classic vibriosis that can affect more than 50 species
of marine animals [9,10], while the latter is a recurrent pathogen
for aquaculture industry associated with warm waters [11]. There are
also other controversial species such as V. alginolyticus because strains
of this species, in addition to being reported as human emerging
pathogen [12,13], and pathogenic for marine animals [14,15], while
other have been suggested for potential use as probiotics in aquaculture
[16,17]. In this case this species will be considered as marine animal
pathogen.
Similarly to other animal production industries, antibiotics are
used in aquaculture to control bacterial diseases, and even with
prophylactic purposes. However, the use and abuse of antibiotics
have led to the proliferation of multiples pathogens resistant to
antibiotics. In 2014, the World Health Organization (WHO) has raised
the alert against the antibiotic resistance [18], and vibrios are not
the exception for this problem. Antibiotic resistance has been reported
in several strains of this genus, from clinical and environmental origin
[19,20,21,22]. The lack of effective treatments to control pathogenic
vibrios resistant to antibiotics has led to the exploration of new
alternatives. One of the most promising options is the use of lytic
bacteriophages to kill pathogenic bacteria [23]. Bacteriophages are
the most abundant biological entity on Earth [24,25], and they play
a fundamental role in the evolution of bacteria [26,27]. Unlike
antibiotics, bacteriophages are speciﬁc; therefore, their application
will not disturb non-target bacterial species. Besides, they are not
toxic and self-restricted, then, will remain in the environment only if
the host bacteria are present [28].
This review summarizes the principal aspects of Vibrio as pathogens
for humans and animals, as well as the principal advances, beneﬁts and
disadvantages in the use of bacteriophages to control these pathogenic
bacteria. We discuss the main challenges that must be overcome in
order to extend its applicability and to advance from an experimental
alternative to a ﬁrst choice treatment.Fig. 1. Primary site of infection of different pathogenic Vibrio affecting humans. There are sev
V. parahaemolyticus are well characterized and their principal virulence factors have been ide
pathogens. Infections produced by vibrios can be acquired by ingestion of contaminated food o2. Principal pathogenic vibrios
2.1. Pathogenic vibrios in humans
There are at least twelve species of Vibrio which are known to
be human pathogens. These species include V. alginolyticus, V. cholerae,
V. cincinnatiensis, V. damsela, V. ﬂuvialis, V. furnisii, V. metschnikovii,
V. mimicus, V. parahaemolyticus and V. vulniﬁcus among others [1,2,3,5,
29,30]. They can cause three major syndromes of clinical illness,
such as gastroenteritis, wound infections and septicemia, being the
most common clinical manifestation a self-limiting gastroenteritis.
V. cholerae, V. parahaemolyticus, V. vulniﬁcus in a greater extent, and
V. alginolyticus, V. ﬂuvialis and V. mimicus in a lesser extent, are the
most important in the clinical microbiology and food safety ﬁelds.
These pathogens have diverse virulence factors to elicit illness in
human, being V. vulniﬁcus and V. alginolyticus primarily associated
with extraintestinal infections [3,12] while V. parahaemolyticus,
V. mimicus and V. cholerae are mainly related to gastroenteritis cases
(Fig. 1) [2,31,32].
Unlike other Vibrio spp.which occur naturally in seafood, V. cholerae
is primarily found in water or food sources contaminated with feces
although it can also be found in the brackish river and coastal waters.
At date, V. cholerae has been the most studied Vibrio due to its impact
on public health and the severity of the cholera disease [1,31]. Among
several virulence factors produced by this pathogen, the main ones
are the cholera toxin (CT) [33], which is provided by a bacteriophage
[34], the toxin co-regulated pilus (TCP) and others that facilitate
its colonization in the intestine, all of them under the control of the
ToxR regulon (Fig. 1) [35,36]. During infection, V. cholerae causes
watery diarrhea, often fatal if untreated, and it is responsible for
approximately between 3–5 million cases and over 100,000 deaths
each year around the world according to the Center for Disease
Control and Prevention (CDC) in 2017 [37].
The most common non-cholera Vibrio infection reported is
V. parahaemolyticus [2,38]. Human infections caused by these bacteria
are mainly produced after the consumption of raw or undercooked
shellﬁsh; only in the USA, this pathogen causes 45,000 illnesses each
year. In fact, since 1996, the appearances of the pandemic clone O3:K6
caused a worldwide pandemic outbreak reaching Southeast Asia, Peru,eral species of pathogenic vibrios infecting humans. Some of them such as V. cholerae or
ntiﬁed while other species such as V. mimicus or V. alginolyticus are considered emergent
r direct contact with the bacteria, colonizing different sites in human body.
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Asiatic origin have also caused diarrhea outbreaks around the world
[42,43]. Virulence in this species is associated to adhesins, various
secretion systems, a thermostable direct hemolysin (TDH) and a
TDH-related hemolysin called TRH (Fig. 1); which collaborate to
produce the illness [2,38,44]; however, these genes have been found
in other species [45]. The diarrhea produced by V. parahaemolyticus is
self-limiting therefore there are several non-reported cases, even in
countries with dedicated surveillance for this pathogen [46]. Rarely, V.
parahaemolyticus can also provoke wound infections in which cases
the use of antibiotics is frequently required.
Finally, V. vulniﬁcus is also a relevant pathogen in clinical
microbiology being the responsible of up to 94% of deaths related
to infections produced by non-cholera Vibrio [3,47]. It possesses a
repertory of virulence factors related to cytotoxicity, motility,
capsule, hemolysins and expression of proteins involved in
attachment and adhesion (Fig. 1). All of them are require to be
expressed in a concerted manner for pathogenesis [3,47]. This
bacterium is found in oysters, shellﬁsh and warm marine waters;
thus, similarly to V. parahaemolyticus, the risk of infection occurs
when people eat raw or uncooked seafood, or when they are
bathing in the sea having a cut or scratch. However, in this case the
primary septicemia produced by this pathogen represents a
mortality rate close to 50% in USA and therefore is considered the
most lethal food-transmitted pathogen in that country, and
possibly in the world [3,47].
Other less recurrent Vibrio pathogens are V. mimicus and V.
ﬂuvialis. The ﬁrst mimics V. cholerae in many biochemical tests
(hence its name), but do not cause epidemic cholera-like disease
and less than 10% of the clinical isolates produce toxin [48]. This
species carries various virulence factors that have been previously
reported in other Vibrio species such as genes coding for ToxR,
ToxS, and a type III secretion system, and it has been suggested
that V. mimicus could be a gene reservoir for other Vibrio pathogens
in the environment [49,50]. On the other hand, although V. ﬂuvialis
is an emerging foodborne pathogen over the world, generating
large outbreaks in Bangladesh and India, and is occasionally
reported in USA. However, its molecular epidemiological features
still remain mostly unknown, and only potential virulence factors
have been proposed in genetic studies [29].
Finally, V. alginolyticus is mainly recognized as a pathogen for ﬁsh;
however, recent epidemiological data suggest an increase in the
incidence of human infections. The documented cases are mainly
associated to otitis and wound infections which may result from
exposure of cuts or scratch to contaminated seawater; however, there
are increasing reports associated to infections with this pathogen due
to consumption of contaminated food [12]. The role of this species as
pathogen for animals will be discussed in the next sections of this
review.
Currently, several reports indicate that the incidence of human
Vibrio infections is increasing in the United States and other countries
[51]. It has been also observed a rising incidence of antimicrobial
resistant pathogenic bacteria in shellﬁsh, including Vibrio species [19,
21]. Many studies have reported different Vibrio pathogens
with resistance to ampicillin, penicillin G, streptomycin, carbenicillin,
kanamycin, cefalotin, sulfadiazine-trimethoprim, chloramphenicol,
erythromycin, ciproﬂoxacin, polymyxin B, azithromycin,
sulfamethoxazole, tetracycline and quinolones [19,21,52,53]. This
situation has motivated the exploration of new alternatives to
conventional treatments with antibiotics, especially for the multiple
antibiotic resistant strains.
2.2. Pathogenic vibrios in animals
Several Vibrio species are also important pathogens for aquaculture
industry, especially in ﬁsh farm, shellﬁsh hatchery and wild shrimp[54,55]. The more relevant are V. anguillarum, V. ordalii and V. harveyi.
The two ﬁrst are mainly associated to ﬁsh infection while the latter is
a major pathogen in shrimp (Fig. 2) [9,10,11].
Both V. anguillarum and V. ordalli are causative agents of a
hemorrhagic septicemia known as classical vibriosis in marine and
freshwater ﬁsh [9,10,54,56]. V. anguillarum is known to infect several
ﬁsh species including various species of economic importance in the
larviculture and aquaculture industry, including salmonids [54,57].
Although more than 20 serotypes have been identiﬁed for this species,
only serotypes O1, O2 and O3 are associated with vibriosis [54,58,59].
The pathogenesis of V. anguillarum is multifactorial and highly
complex requiring multiple crucial virulence determinants, including
those involved in chemotaxis, motility, iron uptake system, hemolysins,
a quorum-sensing system (QS) and sigma factor regulators RpoS
and RpoN among others [9,60]. V. ordalii is genetically closely related to
V. anguillarum [61,62] and vibriosis generated by them can result in
90% mortality if it is not controlled (FAO 1990). In the North Atlantic
area, the impact of vibriosis in the salmonid industry has been reduced
due to the development of vaccination procedures [63]; however,
this remains a signiﬁcant problem in farmed ﬁsh in Europe and Asia
[64,65,66].
V. harveyi is widely distributed in the marine environment, either
as free-living form or associated with marine animals. This pathogen
is responsible of the so called luminous vibriosis infecting a great
variety of aquatic animals including shrimps, ﬁnﬁsh and mollusk,
leading to severe economic losses [11]. As in many Vibrio, virulence
in this species is QS-regulated, modulating virulence factors such as
bioﬁlm formation, motility, production of siderophore, extracellular
products and type III secretion system [67,68]. There are also
reports connecting virulence in this bacterium to the presence of a
temperate bacteriophage [69,70]. Other two Vibrio species
associated to luminous vibriosis are V. campbellii and V. owensii,
both are closely related to V. harveyi and therefore frequently
misidentiﬁed (Fig. 2) [71]. The virulence mechanisms of V. owensii
are largely unknown, but it is considered virulent because it causes
mortality in Penaeus monodon [72]. These three species trigger
bioluminescent vibriosis through numerous associated virulence
factors including toxic extracellular proteins such as proteases,
hemolysins and cysteine proteases, siderophores, bacteriocins resistance
plasmids and chitinases [67,73,74].
V. alginolyticus belongs to the so called harveyi clade [67]. This
bacterium has been involved infections in humans [12], but it is
mostly recognized as an aquaculture pathogen, causing severe
mortalities in shellﬁsh and crustaceans, particularly shrimps. Among
their virulence factors repertory is possible to ﬁnd lipases, proteases,
siderophores and even a TDH [45,75]. Similarly, although V.
parahaemolyticus is mainly recognized as a human pathogen, it has
been also reported as the causing agent of acute hepatopancreatic
necrosis disease (AHPND) which affect multiple shrimp species, such
as P. vannamei and P. monodon. This diseases was ﬁrst reported in
2009 in China and since then has been detected Malaysia, Thailand,
Philippines and also in Mexico generating important economic losses
[76,77]. The pathology of this disease is still unclear, but it has been
associated to V. parahaemolyticus strains that harbor a speciﬁc plasmid
which encode for a binary toxin PirABvp [78].
Other pathogenic Vibrio that can cause mortality events in aquatic
animals are V. tubiashii, which has been reported in shellﬁsh
hatcheries on USA and Chile affecting species like larval paciﬁc oyster
(Crassostrea gigas), Kumamoto oyster (Crassostrea sikamea) and
Geodric clams (Panope abrupta) [79,80]; V. coralliilyticus, closely
related to the previous one [81], is a well-known pathogen for
different coral species, and has been recently associated with disease
in variety species of ﬁsh and shellﬁsh, including oyster larvae, bivalves
larvae, great scallop (Pecten maximus) and rainbow trout (Oncorhynchus
mykiss) [82,83,84]. The list of pathogenic Vibrio for marine species
is very large and can include also Vibrio rotiferianus in O. mykiss
Fig. 2.PrincipalVibrio species pathogenic for aquatic animals and principal type of host. The list of pathogenic vibrios infecting aquatic animals is very large. V. anguillarum andV. harveyi are
the most important species due to their impact in Aquaculture industry, because they infect different species of ﬁsh and shellﬁsh of economic importance. Some of these species, such as
V. anguillarum and V. ordalii, or V. coralliilyticus and V. tubiashii, are very close related, making their identiﬁcation difﬁcult.
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gigas [85] among others (Fig. 2).
Similarly to the situationwith pathogenic vibrios for humans, in this
case antibiotics have been the ﬁrst line treatment to control these
pathogens. The extensive use of antibiotics in the aquaculture industry
has raised the concern about the occurrence of antibiotic resistant
pathogens [86]. Several Vibrio species resistant to antibiotics have
been reported [19,20,21], and some cases the lack of effectiveness
of these antimicrobials has led to massive mortalities in shrimp
aquaculture [87,88]. In this regard, the implementation of new
alternatives, such as bacteriophages or vaccines, to control pathogenic
vibrios represents an important step in the transition to a more
sustainable aquaculture industry.
3. Bacteriophages for controlling pathogenic vibrios
3.1. Phage therapy to control pathogenic vibrios infecting humans
Theﬁrst report about theuse of phages to control a pathogenicVibrio
in humans was against V. cholerae, and it was described by Felix
d'Herelle. During this work, when the cholera-patients were treated
with oral doses of bacteriophage the mortality rate was 8.1%, while
in the control patients treated with other medicines it was 62.9%.
The mortality rate in the phage treated group was zero if treatment
occurred within 6 h of appearance of the ﬁrst symptoms [89].
In parallel, Asheshov performed a similar experience in different
locations but with conﬂicting results. While in one location the
treatment was successful, the phages treatment did not work in the
other location. The authors mentioned that although the phage
was able to arrest the progress of disease it was more effective used
with prophylactic rather than a therapeutic purposes [90]. Later in
the years 1958–1960, animal passaged phage preparations were
successfully used in treating cholera-patients. An initial intravenous
or intramuscular phage doses with saline buffer followed by oral
doses for 3 d displayed positive results [91]. Despite the successfulexperiences, all the studies concluded that to understand better the
nature of bacteriophage-host interactions in vivo, a good animal model
of cholera phage therapy is needed.
The use of animal models has been very important to study the
phage therapy to control V. cholerae [92,93] especially, considering
that it is not ethically acceptable to experimentally infect humans
with bacterial pathogens for trials purposes (Table 1). Nowadays,
rabbits and mice are used like phage therapy models [92,93,94]. The
ﬁrst challenge using this approach inoculated rabbits with 109 CFU/mL
of V. cholerae strain MAK 757 in each of the six controls and phage
treated rabbits. In the phage-treated rabbits, besides the bacteria, they
gave 108 PFU/mL cocktail of phages. Those animals developed mild
to low diarrhea, and fewer pathological changes in the intestine
than non-phage treated individuals. The authors concluded that
this study was the ﬁrst direct indication of phage multiplication in an
open system such as the intestine infected by a V. cholerae strain.
Same group later used an adult mouse model to test different oral
approach to treat V. cholerae infection, including cocktail phages
against the bacteria and antibiotics [95]. Daily application of both
cocktail of phages administered at the MOI (multiplicity of infection)
of 0.1 (1 × 108 PFU/mL) and ciproﬂoxacin antibiotic (40 mg/kg) were
effective in the reduction of bacterial load, although the bacterial load
reduction was greater in antibiotic treated animals. Recently, Yen et al.
proved the prophylactic efﬁcacy of a cocktail of three phages named
ICP1, ICP2 and ICP3 in mice (Table 1). The results showed that oral
administration of phages up to 24 h before infection with V. cholerae
reduce the bacterial colonization in the intestinal tract and prevents
cholera-like diarrhea [91]. These results suggest that phages can be
effective against V. cholerae as a prophylactic or as a treatment.
There are several reports about phages infecting V. parahaemolyticus
[96,97,98,99]; however, their use in phage therapy to control infections
in humans have been less explored, and always used on animal models
(Table 1). Recently, the therapeutic potential of a phage named pVp-1
was studied in a mouse model using a multiple-antibiotic-resistant
V. parahaemolyticus O3:K6 pandemic clinical strain [100]. They
Table 1
Phage therapy challenges in different Vibrio species pathogenic for humans.
Vibrio species Challenge model Type of phage application (PFU/mL) Results Reference
V. cholerae Human Oral (unknown) Protection [86]
V. cholerae Human Oral (unknown) Protection [105]
V. cholerae Human Oral (unknown) Relative protection [106]
V. cholerae Human Oral, after animal passage (unknown) Protection [88]
V. cholerae Human Oral (1012) Protection [107]
V. cholerae Human Oral (108–109) Protection [107]
V. cholerae Adult rabbit Inoculation into ileal loop (1011) Unsuccessful [108]
V. cholerae Adult rabbit Oral (108) Protection [91]
V. cholerae Adult mice Oral (108) Protection [92]
V. cholerae Infant mouse
Infant rabbit
Oral (109) Bacterial load reduction in mouse
Protection in rabbit
[89]
V. parahaemolyticus Adult mouse Oral (108) Protection [97]
V. parahaemolyticus Oyster Bath (108) Bacterial load reduction [98]
V. vulniﬁcus Adult mice Intravenous (108) Protection [99]
V. vulniﬁcus Oyster Batha Bacterial load reduction [100]
a Phage concentration was not speciﬁed.
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bacterial and phage titers during phage therapy and observed the
immune response induced by phage burst. The results showed that
phage-treated mice presented protection from a V. parahaemolyticus
infection and survived lethal doses of oral and intraperitoneal
bacterial challenges. Despite the successful results, the authors
emphasized the need to establish adequate phage preparation
methodologies such as the puriﬁcation and removal of endotoxins for
safety in phage therapy to prevent anaphylactic responses. Same
authors with different approach used the same phage pVp-1 to avoid
V. parahaemolyticus infection due to consumption of raw
contaminated seafood, especially oysters. In this case the authors
designed an artiﬁcial contamination model simulating potentially
contamination events during oyster processing [101]. This method
showed that bacterial growth can be reduced ﬁve orders of magnitude
when phages were added through bath immersion and six orders of
magnitude when phages were added over the surface of the samples.
In both cases, bacteria were added prior to phage treatment indicating
phages could be efﬁcient even after the pathogen started the infection.
Finally, in the case of V. vulniﬁcus phage therapy has been driven
using an infection model of iron-dextran-treated mice [102]. The
animals were injected subcutaneously with 106 CFU (10 times the
lethal dose of V. vulniﬁcus), while phages were administered at doses of
108 PFU through intravenous injection, either simultaneously or
at various times after infection. The authors showed that phage
treatment has therapeutic potential for both localized and systematics
infections preventing both local and systemic disease reaching the
optimal protective effect when administered within 3-h post bacterial
infection. Interestingly, only two out of three phages tested were
effective in normal conditions. The third phage was able to lyse
the bacteria only in presence of seawater, and was ineffective
to protect mice during the challenges. Similarly to the case of
V. parahaemolyticus, bacteriophages have been also used to reduce the
load of V. vulniﬁcus in extracts of eastern oyster (Crassostrea virginica)
[103]. In this case, the oyster extract also have antimicrobial properties
against this bacterium, and the combined effect with bacteriophages
allow a bacterial load reduction from 106 to 101 CFU/mL after 18-h
incubation at 4°C. These results add evidence that phage therapy is a
viable alternative treatment for human V. vulniﬁcus infections
or seafood depuration. However, these also remark the importance
of study the effectiveness of different phages and administration
conditions for phage therapy like the proper time for phage addition.
There are other Vibrio species considered opportunistic pathogens in
humans such as V. ﬂuvialis [4] or V. furnissii [104] for which no phage
therapy studies have been conducted yet. However, vibriophages
infecting and controlling these bacteria have been isolated andcharacterized. For example, bacteriophages infecting V. ﬂuvialis, which
is considered as an emerging human pathogen [3], were characterized
for bacterial typing purposes but candidates for phage therapy have
remained unexplored [105]. Phages infecting Vibrio species in the
environment have been well documented [99,106,107]. Thus, it is
possible to expect new studies about phage therapy in these emerging
Vibrio pathogens.
3.2. Phage therapy to control pathogenic vibrios infecting animals
Most of the animal species infected by vibrios reported are related
to aquaculture industry. Therefore the vast majority of examples
presented are associated with this productive area. Fish, mollusks
and crustaceans of economic importance can be infected by Vibrio
species such as V. harveyi, V. anguillarum and the close related species
V. ordalii, V. splendidus, V. coralliilyticus and more recently
V. cyclitrophicus. Among them, V. harveyi is the most common target.
To date, there are several articles about isolation and characterization
of V. harveyi phages or about the use of phages to control this
bacterium where crustaceans are the preferred infection model [106,
112,113,114,115,116,117].
In 2000, Oakey and Owens described the phage VHML able to infect
V. harveyi [118]. However, this phagewas not suitable for phage therapy
since it was shown that its presence may confer virulence to several
strain of V. harveyi [70]. Later on, in 2006, bacteriophages isolated
from shrimp farm waters demonstrated to increase the viability
of P. monodon larvae infected with V. harveyi up to 80% in comparison
to 25% of larvae without phages [112]. This was the ﬁrst attempt to
demonstrate the potential use of bacteriophages to control Vibrio
pathogens in aquaculture. Afterwards similar approach was used
with different Vibrio species (Table 2). By contrast to what happen
with vibrios infecting humans, in this case most of the challenges have
been done using the actual host of the bacteria and in conditions
equal or similar to aquaculture farms [112,116,119,120,121],
these include phage therapy assays against V. splendidus using sea
cucumber (Apostichopus japonicus) farming [121] and assays against
V. coralliilyticus using the non-commercial coral host (Acropora
millepora) (Table 2) [119]. In the case of V. splendidus, three
bacteriophages named PVS-1, PVS-2 and PVS-3 were able to inhibit
the growth of the host and other 3 Vibrio species. A cocktail of
these phages increases the survival of sea cucumber infected with
V. splendidus from 18% to 82% in the phage-treated condition, which
was indistinguishable to antibiotic-treated sea cucumber [121]. A
similar approach was used by same authors to prevent infections
with V. cyclitrophicus [122]. In this case, a single bacteriophage named
vB_VcyS_Vc1 was able to increase the survival rate of juvenile
Table 2
Examples of phage therapy in Vibrio species pathogenic to animals.
Vibrio species Challenge model Type of phage application (PFU/mL) Results Reference
Vibrio harveyi Penaeus monodon Batch (109) Increased animal survival [109]
Vibrio harveyi Penaeus monodon Direct addition (106) Increased larvae survival than antibiotic treatment [111]
Vibrio harveyi Shrimp post larvae Direct addition (1010) Increased shrimp survival [113]
Vibrio harveyi Haliotis laevigata Bath (102) 70% increase animal survival [114]
Vibrio splendidus Sea cucumber (Apostichopus japonicus) Injection of Single and Cocktail (109) Increased animal survival [118]
Vibrio coralliilyticus Acropora millepora Bath (109) Prevent photo inactivation and coral tissue lysis [116]
Vibrio cyclitrophicus Sea cucumber (Apostichopus japonicus) Bath (105) Increased animal survival [119]
Vibrio alginolyticus Sea cucumber (Apostichopus japonicus) Direct addition (105–107) Increased animal survival [124]
Vibrio alginolyticus Artemia salina Bath Cocktail phage (106) Increased animal survival [117]
Vibrio anguillarum Salmo salar Direct addition (106) Increased animal survival [120]
Vibrio anguillarum Danio rerio larvae Direct addition (108) Moderate increase in larvae survival [121]
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were added through food, injection or bath immersion respectively,
evidencing that the method for phage administration can be determining
in the results obtained.
Phages have been also used to protect against V. anguillarum
infections. In 2013, Higuera et al. [123] showed that a phage named
CHOED was able to increase Salmo salar ﬁsh survival infected with
the bacteria from 10 to even 100% rates in controlled conditions.
Moreover, in aquaculture conditions, the phage was able to increase
survival of ﬁshes from 60 to 100% rates after a 20-d challenge;
this was the ﬁrst successful attempt to demonstrate the use of
bacteriophages to control Vibrio pathogens in salmonids [123]. Similar
results were obtained by Silva et al. but this time using zebraﬁsh
larvae as infection model [124]. In this case, the mortality rate
observed in the larvae infected with the bacteria plus phage was less
than 3% and was indistinguishable from the control condition
(non-infected and without phages), while the infected larvae without
phage addition showed a mortality rate of 17%. The lower mortality
observed is probably because zebraﬁsh is not a common host for
V. anguillarum. However, these results suggest that phage therapy can
be an alternative to protect ﬁsh against these bacteria in different
developmental stages.
Besides the standard approach to phage therapy, that determines if
phages can protect against bacterial infection. There are several
reports about different factors that may inﬂuence and be important
for the success of phages to control pathogenic bacteria. For instance,
V. harveyi have been the subjects of studies focused on determine
the effect of dissolved solids and temperature in phage therapy
experiments, or to determine if phages are able to inhibit the bioﬁlm
formation in this bacterium [114,125]. Another example included
experiments to test if the isolated phages against V. harveyi were lytic
against potentially beneﬁcial bacteria [126]. This issue is very relevant
to assure the safety of phage application because in the ideal scenario
the normal microbiota from the animal should not be disturbed.
A ﬁnal interesting case is V. alginolyticus, since it has been
reported as a pathogen for animals [14,15] and humans [12,13].
Zhang et al. showed in 2015 that bacteriophages against this
species were able to increase the survival of sea cucumber
(A. japonicus) from 3% in untreated-phage individuals up to 73%
when phages were added at MOI of 10 [127]. More recently, it was
reported that two bacteriophages ϕSt2 and ϕGrn1 against the
V. alginolyticus strain V1 were able to signiﬁcantly reduce the total
Vibrio load in Artemia salina cultures [120]. However, there are
reports suggesting that speciﬁc strains of this species can be used
as probiotics in shrimp culture [16,17], evidencing the extreme
diversity of this genus and species [128].
All these examples suggest that phage therapy can be an excellent
alternative to control pathogenic vibrios, both from humans and
animals. However, this approach is not widely used yet and is mainly
still in a research stage. In the next section, we explore which are the
main challenges ahead in order to reach efﬁcient treatments against
vibrios using bacteriophages.3.3. Future challenges in phage therapy
To date, a search in PubMed with the words “phage”, “therapy” and
“Vibrio” shows 40 results. Additionally, there are 1879 patents or
patents in progress about the use of bacteriophages and its possible
use in phage therapy [129]. Moreover, currently there are several
commercially available products based in bacteriophages. However,
unlike Eastern Europe, the use of bacteriophage as antimicrobials
is still in development and subject to general discussion. There are
still some areas that require more development and studies. These
are related mainly to the proliferation of resistant bacteria, methods
of administration, and a regulatory frame for products based on
bacteriophages.
Bacteriophage resistance was reported soon after the discovery of
bacteriophages, and since then, has been subject of several studies
[130,131]. In the context of phage therapy, several alternatives
have been proposed to overcome this problem, such as the use of
bacteriophage cocktails [93,132]. The normal frequency of resistant
bacteria appearance is between 10−6 and 10−8 then, if the
bacteriophages used in the cocktail have different routes of infection,
the probability of proliferation of resistant bacteria will be reduced to
around 10−14 or even less depending on how many phages are used
in the cocktail. In 2012, Gu et al. reported a method to generate
cocktail of bacteriophages for use in phage therapy which reduce the
probabilities of resistant bacteria proliferation [133]. This method
consisted in sequential isolation of new bacteriophages against the
bacteriophage resistant variants of the host Klebsiella pneumoniae.
Each new phage isolated will target a variant of K. pneumoniae derived
from the original host and resistant to the last bacteriophage isolated.
In this way, they generated a cocktail composed by bacteriophages
able to infect all the possible resistant variants of the original
host. This method has great potential against single pathogens,
however, can be very laborious if the targets are multiple pathogens
or different strains of the same bacteria. Other authors have proposed
the optimization of bacteriophage cocktails studying potential
interactions between phages to predict synergisms or interference
between phages in cocktails [134]. While these efforts try to avoid
the proliferation of resistant bacteria other studies are focus in the
characterization of resistant bacteria. Several reports show that
bacteriophage resistant strains can have a reduction in their virulence
probably as a consequence of the acquired resistance [130,135,136];
however, this situation is not common to all bacteria [137].
In recent years, numerous researches have been focused in
CRISPR-cas system (For further details see [138]); this so called
bacterial immune system is widely spread in bacterial species [139],
including Vibrio [140,141,142] and therefore can be considered a
big obstacle for phage therapy because bacterial pathogens can
acquire resistance after multiples treatments with the same phage.
Fortunately, for phage therapy enthusiast, phages have evolved
different mechanisms to avoid or repress the CRISPR-cas system. Five
genes with anti-CRISPR activity were described in bacteriophages
against Pseudomonas aeruginosa and homologs to these genes were
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144]. Bacteria and bacteriophages have a history of co-evolution, then
for each defense mechanisms generated by bacteria, bacteriophages
will develop a strategy to surpass the defense.
Another challenge for phage therapy is to develop efﬁcient
mechanisms for phage administration depending on where the
phages will be applied. For vibrios, the alternatives are therapy in
humans and aquaculture systems. In 2006, the FDA recognize a
bacteriophage preparation against Listeria monocytogenes as GRAS
(Generally Recognized As Safe GRAS Notice 000198) authorizing its
addition to ready-to-eat food. Since then, this status has been granted
to ﬁve others preparations, recognizing they represent no risk for
human health. Concerning actual trials of phage therapy in humans,
there are reports from 1930 in India about the use of bacteriophages
to control cholera outbreaks [110,145], but most of the experience
comes from Eastern Europe countries, especially Georgia where
the use of bacteriophages is part of the National Health System [146].
In most of the cases, bacteriophages have been applied over the skin
to treat wound infections or orally for systemic diseases [147]. In the
ﬁrst case, phages can be applied directly over the wound or through
phage soaked dressings complementarily to wound care treatments in
order to get successful results. In the second case bacteriophages can
reach a systemic distribution being able even to cross the blood–brain
barrier [132,147]. In this situation, the main obstacle is the acidic
environment of gastric ﬂuids which can affect the viability of the
phages. The encapsulation with alginate beads and other polymers can
be a potential solution for this problem as has been proposed previously
[148,149]. Other option explored is the utilization of bacteriophages
from the same environment where they will be used [150].
The other main ﬁeld of application of bacteriophages regarding
Vibrio spp. is aquaculture. In this case, bacteriophages have been
applied directly to the water [112,114,123], through intraperitoneal
injection [151,152] or embedded with food [153,154]. All these
three methods can have strengths and weakness depending on
the aquaculture system. For example, application to the water can
be the easiest way in recirculation aquaculture systems (RAS),
however is not suitable for open water systems. On the other hand,
the intraperitoneal injection can be a time-consuming method
while application of phage-embedded food could affect bacteriophage
release, viability, or even the food consumption by the cultured
species. Therefore, each case should be considered particularly
depending on the aquaculture system and the nature of the
bacteriophages to apply.
Finally, another major obstacle for phage therapy is to deal with the
lack of a speciﬁc regulatory frame designed considering the special
nature of bacteriophages. Despite that bacteriophages are considered
to use as antimicrobials, they have special features as self-replication,
self-restriction and no toxicity [155,156], and therefore cannot be
classiﬁed or regulate as antibiotics. The lack of knowledge and
regulation had to lead to bacteriophages to be classiﬁed as different
substances hampering clinical trials [157]. This situation has
motivated a group of important researchers from Europe to claim
for adequate regulations generating efﬁcient treatments using
bacteriophages [158].
4. Conclusion
Among the genus Vibrio, there are important bacterial species that
can be pathogenic for humans and economically important animals.
Worryingly, several reports indicate that the occurrence of Vibrio
infections is increasing. Parallel, a rising incidence of antimicrobial
resistant pathogenic bacteria has been observed. The evidence
summarized in this work suggests that bacteriophage can be
considered as a consistent alternative to control pathogenic vibrios,
especially in the antibiotic resistance era. However, in spite of the
information and the experience generated, there are still somedrawbacks that must be overcome in order to generate safe, efﬁcient
and reproducible treatments. The achieve of these goals require joint
efforts from researchers, but also from governing entities which must
implement adequate regulations that allow generating reliable and
efﬁcient treatments oriented to replace or reduce the use and misuse
of antibiotics.
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